Single Bout Exercise in Children with Juvenile Idiopathic Arthritis: Impact on Inflammatory Markers

Table 1

Baseline demographics, clinical characteristics, and baseline laboratory findings.

Age (years)	Sex	BMI (kg/m^2)	score	JIA subtype	Disease duration (months)	Concomitant DMARDs	hs-CRP (mg/L)	Heart rate during exercise: min–max (bpm)
11	F	14.8	−1.4	Psoriatic	16.8	MTX	0.24	141–149
10	M	18.1	+0.6	ERA	14.1	Sulfasalazine	<0.16	144–150
8	F	21.7	+1.8	pJIA RF−	4.9	MTX	1.4	142–152
9	M	15.5	−0.4	ERA	35.6	MTX	<0.16	143–152
14	F	19.7	+0.2	pJIA RF−	9.0	MTX	<0.16	140–149
14	M	20.1	+0.3	Psoriatic	40.1	Infliximab + leflunomide	0.33	141–149
16	F	21.1	+0.2	ERA	25.8	NSAIDs	0.53	138–147
9	M	21.3	+1.7	oJIA	55.2	NSAIDs	<0.16	140–151
15	F	23.1	+0.9	ERA	20.7	NSAIDs	<0.16	140–149
13	F	19.4	+0.2	pJIA RF+	23.0	MTX + etanercept	<0.16	138–150
12	F	16.9	−0.5	Undif	67	None	<0.16	139–151
16	F	24.4	+1.0	Undif	20.5	Etanercept	0.22	138–147

JIA: juvenile idiopathic arthritis; oJIA: oligoarticular JIA; pJIA RF−: rheumatoid factor-negative (RF−) polyarticular JIA; pJIA RF+: rheumatoid factor-positive (RF+) polyarticular JIA; ERA: enthesitis-related arthritis; Psoriatic: psoriatic JIA; Undif: undifferentiated; DMARDs: disease-modifying antirheumatic drugs; MTX: methotrexate; NSAIDs: nonsteroidal anti-inflammatory drugs; hs-CRP: high-sensitivity C-reactive protein; bpm: beats per minute. Normal value < 3.0 mg/L. Values of <0.16 are below the minimum detectable limit of the kit.